Bank of New York Mellon Corp Sells 14,083 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Bank of New York Mellon Corp trimmed its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 3.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 385,501 shares of the specialty pharmaceutical company's stock after selling 14,083 shares during the period. Bank of New York Mellon Corp owned approximately 0.69% of Supernus Pharmaceuticals worth $12,625,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Vident Advisory LLC increased its position in shares of Supernus Pharmaceuticals by 2.2% during the fourth quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company's stock valued at $520,000 after buying an additional 309 shares during the period. Summit Investment Advisors Inc. lifted its position in Supernus Pharmaceuticals by 7.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 5,253 shares of the specialty pharmaceutical company's stock valued at $190,000 after buying an additional 369 shares during the period. Bank of Montreal Can raised its position in shares of Supernus Pharmaceuticals by 6.6% in the 4th quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company's stock worth $275,000 after purchasing an additional 473 shares during the last quarter. HighTower Advisors LLC raised its position in shares of Supernus Pharmaceuticals by 7.3% in the 4th quarter. HighTower Advisors LLC now owns 9,130 shares of the specialty pharmaceutical company's stock worth $330,000 after purchasing an additional 624 shares during the last quarter. Finally, Raiffeisen Bank International AG purchased a new position in Supernus Pharmaceuticals in the 4th quarter worth about $25,000.

Analysts Set New Price Targets

Separately, Wall Street Zen lowered Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Sunday.

Supernus Pharmaceuticals Stock Down 1.7%

Supernus Pharmaceuticals stock traded down $0.56 during mid-day trading on Tuesday, hitting $32.67. The company's stock had a trading volume of 728,575 shares, compared to its average volume of 494,879. The stock has a market capitalization of $1.83 billion, a P/E ratio of 29.43 and a beta of 0.70. Supernus Pharmaceuticals, Inc. has a twelve month low of $27.05 and a twelve month high of $40.28. The stock's fifty day moving average price is $32.41 and its two-hundred day moving average price is $33.62.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.